| Document |
Document Title |
|
WO/2021/084472A1 |
Electrochemiluminescence (ECL) lable molecules, detection reagents labled with the ECL label molecules, and methods of using the ECL label molecules and detection reagents labeled with the ECL label molecules for bioanalytical assays, es...
|
|
WO/2021/085528A1 |
Provided is a CD4 mimic compound which has more improved in vivo kinetics and improved efficacy in anti-HIV treatment. Provided are: a compound represented by formula (I) [in the formula, R1 represents -C2H4(OC2H4)n-OCH3 or CmH2m+1, R2...
|
|
WO/2021/084217A1 |
The present invention provides processes for the preparation of a hydrochloric acid salt of compound of formula (2): (I) Compound of formula (2) wherein: R1 is selected from the group consisting of -H, an unsubstiuted straight-chain C1-C...
|
|
WO/2021/066435A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...
|
|
WO/2021/057882A1 |
A compound of formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising these compounds. The compound is used in the treatment, prevention or amelioration of diseases or conditions su...
|
|
WO/2021/057832A1 |
Privided is a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.
|
|
WO/2021/059017A1 |
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...
|
|
WO/2021/055630A1 |
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...
|
|
WO/2021/049654A1 |
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), a first light emitting layer (51) and a second light emitting layer (52) that is arranged between the first light emitting laye...
|
|
WO/2021/029158A1 |
The purpose of the present invention is to provide: a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays and which generates a superacid bis-sulfonamide, and which is highly soluble in a resist ...
|
|
WO/2021/029914A1 |
The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' eng...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/026380A1 |
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...
|
|
WO/2021/026378A1 |
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...
|
|
WO/2021/026098A1 |
Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, suc...
|
|
WO/2021/026377A1 |
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...
|
|
WO/2021/026375A1 |
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...
|
|
WO/2021/024925A1 |
The present invention aims to provide: a chemically amplified positive photosensitive resin composition that contains an acid generator having excellent solvent solubility and can readily form a resist pattern having excellent mask linea...
|
|
WO/2021/021953A2 |
Described herein are small molecule agonists of dopamine receptor D1 that inhibit YAP/TAZ, compositions, and methods of using these compounds and compositions.
|
|
WO/2021/009232A1 |
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlli...
|
|
WO/2021/009229A1 |
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3,W, Y, Z & G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for cont...
|
|
WO/2021/009048A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2021/007146A1 |
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. The antagonists (such as a hexahydro pyrido[3,4-b]indole, AZD9496, RAD-1901, ARN-810, endoxifen, or fulvestrant) may be an inhibit...
|
|
WO/2020/261021A1 |
Described are polymerizable fused tricyclic compounds of formula I: wherein R1, R2, R3, m, n, t, and rings B, C, and D are as defined herein. The compounds absorb various wavelengths of ultraviolet and/or visible light (such as high ener...
|
|
WO/2020/263822A1 |
The invention provides a series of conformationally stable and selective, irreversible kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selec...
|
|
WO/2020/257734A1 |
The disclosure relates, in certain aspects, to the discovery of compounds that can be used to inhibit β-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-48. In certain embodiments, these compounds can b...
|
|
WO/2020/254507A1 |
Compounds of general Formula (I) wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use.
|
|
WO/2020/249079A1 |
A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase alloster...
|
|
WO/2020/243224A1 |
The present invention relates to novel combinations. The invention also relates to such combinations for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseased caused by pathogenic mycobacteria su...
|
|
WO/2020/242051A1 |
Disclosed are: a compound; a composition comprising the compound; and a photodynamic therapy method for inactivating or killing tumor cells using the composition.
|
|
WO/2020/234276A1 |
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...
|
|
WO/2020/234273A1 |
The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]diox
olo[4',5':5,6]benzo[1,2-g]quinoline with formula (Ib), (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[...
|
|
WO/2020/234277A1 |
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...
|
|
WO/2020/221570A1 |
The present invention relates to a compound, and to an organic semiconductor layer comprising this compound, suitable for use as an organic semiconductor layer for electronic devices, and a method of manufacturing the same, wherein the c...
|
|
WO/2020/223715A1 |
In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated...
|
|
WO/2020/223136A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of 7α nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2020/212408A1 |
The present invention relates to an organic semiconducting material comprising a compound comprising at least one dibenzo [c,h) acridine group and at least one CN-group, organic electronic devices comprising the same and display devices ...
|
|
WO/2020/186961A1 |
Disclosed in the present invention are a bulleyaconitine D crystal and a preparation method therefor. Figure 1 shows an X-ray powder diffraction spectrum of the crystal according to the present invention, the spectrum being measured with...
|
|
WO/2020/186960A1 |
A bulleyaconitine A crystalline form C, and a preparation method therefor. An X-ray powder diffraction spectrum of the crystalline obtained by measurement using a Cu-Kα ray is as shown in fig. 1. The preparation method therefor comprise...
|
|
WO/2020/186962A1 |
Provided is a crystal form E of bulleyaconitine A and a preparation method for the crystal form E of bulleyaconitine A. An X-ray powder diffraction spectrum of the crystal form measured by Cu-K α-ray is as shown in FIG. 1. The crystal f...
|
|
WO/2020/186963A1 |
Crystal form G of bulleyaconitine A and a preparation method therefor. Crystal form G of bulleyaconitine A was prepared by adding bulleyaconitine A to a mixed solution of methanoic acid and n-heptane and dissolving, stirring at a low tem...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/184649A1 |
Provided as a material able to produce an optical member, such as a lens having a high light transmittance, is a solvate of a compound represented by general formula 1, wherein the solvent contains a nitrogen atom-containing organic comp...
|
|
WO/2020/169648A1 |
The present invention relates to compounds of Formula (I), 5 wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controll...
|
|
WO/2020/165233A1 |
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for contro...
|
|
WO/2020/165102A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2020/160134A1 |
Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by i...
|
|
WO/2020/124688A9 |
Provided in the present invention are full-spectrum high-brightness and high-stability fluorescent dyes, the dyes being one or several of the following mixed according to any ratio: 4-amido substituted naphthalimide dye, bisalkoxy substi...
|
|
WO/2020/143198A1 |
Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used ...
|
|
WO/2020/139291A1 |
The present patent application discloses naphthalimide derivatives and in particular e.g. N-aryl-substituted naphthalimidopropylamine derivatives (i.e. 2-[3-(amino)propyl]-1H-benz[de]isoquinoline-1,3(2H)- dione derivatives) such as e.g. ...
|
